Menu
← Oncology Approval Tracker
FDA DECISION ·
Tukysa + trastuzumab + capecitabine
tucatinib + trastuzumab + capecitabine · Seattle Genetics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with unresectable advanced or metastatic HER2-positive breast cancer, including those with brain metastases, after at least one HER2-directed regimen in the metastatic setting.
LAMPGEN ANALYSIS
Why it matters
Established a HER2 regimen backed by prospective evidence in patients with brain metastases.
What research teams should watch
Record intracranial disease and prior HER2 treatment and align brain imaging with response assessments.
PRIMARY RECORDS